Skip to main content

Advertisement

Table 5 Patients with emerging mutationsa in patients with failure,b by baseline Q80K polymorphism (ITT population)

From: Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study

n/N (%) Phase 2/3 group (N = 125) Phase 1 group (N = 16)
Failure 38 10
Sequencing data
 Availablec 33/38 8/10
 Not available 5/38 2/10
Emerging mutations at failure 27/33 (81.8) 7/8 (87.5)
 Without Q80K at baseline 24/33 (72.7) 7/8 (87.5)
  D168V 9/33 (27.3) 4/8 (50.0)
  Q80L + R155K 2/33 (6.1) 0/8
  D168E/V + F169I 1/33 (3.0) 0/8
  Q80L + D168V 1/33 (3.0) 0/8
  Q80L + I132L + R155K 1/33 (3.0) 0/8
  Q80R 1/33 (3.0) 0/8
  Q80R + D168E 1/33 (3.0) 0/8
  Q80R + D168E/V 1/33 (3.0) 0/8
  Q80R + R155K 1/33 (3.0) 0/8
  R155K 1/33 (3.0) 0/8
  R155K + D168A/N/T 1/33 (3.0) 0/8
  R155K + D168E/V + I170V 1/33 (3.0) 0/8
  R155K + N174 K 1/33 (3.0) 0/8
  R155K + N174S 1/33 (3.0) 0/8
  R155Q + D168V 1/33 (3.0) 0/8
  D168A/V + I170V 0/33 1/8 (12.5)
  Q80K 0/33 1/8 (12.5)
  S122R + R155K 0/33 1/8 (12.5)
 With Q80K at baseline 3/33 (9.1) 0/8
  R155K 2/33 (6.1) 0/8
  D168E 1/33 (3.0) 0/8
No emerging mutation at failure 6/33 (18.2) 1/8 (12.5)
 Without Q80K at baseline 6/33 (18.2) 0/8
 With Q80K at baseline 0/33 1/8 (12.5)
  1. aConsidering NS3 positions 36, 41, 43, 54, 55, 80, 107, 122, 132, 138, 155, 156, 158, 168, 169, 170, 174, and 175
  2. bFailures: all patients with failure
  3. cOnly patients with baseline and post-baseline sequencing data are considered
  4. ITT intent-to-treat